Reviewing Crinetics Pharmaceuticals Inc. (CRNX)’s and Cellectis S.A. (NASDAQ:CLLS)’s results

Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Cellectis S.A. (NASDAQ:CLLS), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation of the two firms.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Crinetics Pharmaceuticals Inc. 2.43M 236.59 27.11M -0.91 0.00
Cellectis S.A. 21.43M 39.37 78.69M -2.11 0.00

Table 1 demonstrates Crinetics Pharmaceuticals Inc. and Cellectis S.A.’s gross revenue, earnings per share and valuation.


Table 2 represents Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Cellectis S.A. (NASDAQ:CLLS)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Crinetics Pharmaceuticals Inc. -1,115.64% 0% 0%
Cellectis S.A. -367.20% -23% -18.8%


Crinetics Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 31 and 31 respectively. The Current Ratio and Quick Ratio of its competitor Cellectis S.A. are 11.2 and 11.2 respectively. Crinetics Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Cellectis S.A.

Analyst Recommendations

Crinetics Pharmaceuticals Inc. and Cellectis S.A. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Crinetics Pharmaceuticals Inc. 0 0 1 3.00
Cellectis S.A. 0 2 1 2.33

The upside potential is 67.79% for Crinetics Pharmaceuticals Inc. with consensus target price of $40. Competitively Cellectis S.A. has a consensus target price of $35.25, with potential upside of 76.43%. The information presented earlier suggests that Cellectis S.A. looks more robust than Crinetics Pharmaceuticals Inc. as far as analyst belief.

Insider & Institutional Ownership

Crinetics Pharmaceuticals Inc. and Cellectis S.A. has shares owned by institutional investors as follows: 98.6% and 29.4%. Insiders owned 5.66% of Crinetics Pharmaceuticals Inc. shares.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Crinetics Pharmaceuticals Inc. 2.61% -8.83% -31.68% -22.38% 0% -20.11%
Cellectis S.A. 12.66% 10.81% -10.39% -33.67% -37.98% 17.6%

For the past year Crinetics Pharmaceuticals Inc. has -20.11% weaker performance while Cellectis S.A. has 17.6% stronger performance.


Crinetics Pharmaceuticals Inc. beats on 7 of the 12 factors Cellectis S.A.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Cellectis S.A., a gene-editing company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL) and CLL. The companyÂ’s products also comprise UCART123 for acute myeloid leukemia indications and blastic plasmacytoid dendritic cell neoplasm; UCARTCS1 for multiple myeloma (MM) indications; UCART22 for ALL; and UCART38 for T-cell ALL and MM. In addition, it focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology. The company has strategic alliances with Pfizer Inc. to generate CAR T-cells in the field of oncology; Les Laboratoires Servier SAS to develop and commercialize product candidates; The University of Texas MD Anderson Cancer Center to research and develop novel cellular immunotherapies for patients suffering from various liquid tumors; and Cornell University to accelerate the development of a targeted immunotherapy for patients with acute myeloid leukemia. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.